Olaparib Tablets Maintenance Monotherapy Ovarian Cancer patients after Complete or Partial Response to Platinum Chemotherapy - L-MOCA

Study identifier:D0816C00016

ClinicalTrials.gov identifier:NCT03534453

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (L-MOCA)

Medical condition

relapsed ovarian cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Olaparib 300mg tablets

Sex

Female

Actual Enrollment

229

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 29 May 2018
Estimated Primary Completion Date: 31 Dec 2024
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria